Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 206

Similar articles for PubMed (Select 20946630)

2.

HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells.

Ward CS, Eriksson P, Izquierdo-Garcia JL, Brandes AH, Ronen SM.

PLoS One. 2013 Apr 23;8(4):e62610. doi: 10.1371/journal.pone.0062610. Print 2013.

3.

Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.

Rodrigues LM, Chung YL, Al Saffar NM, Sharp SY, Jackson LE, Banerji U, Stubbs M, Leach MO, Griffiths JR, Workman P.

BMC Res Notes. 2012 May 23;5:250. doi: 10.1186/1756-0500-5-250.

4.

Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.

Beloueche-Babari M, Arunan V, Jackson LE, Perusinghe N, Sharp SY, Workman P, Leach MO.

Oncotarget. 2010 Jul;1(3):185-97.

5.

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.

Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM.

J Natl Cancer Inst. 2003 Nov 5;95(21):1624-33.

6.

Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.

Al-Saffar NM, Troy H, Ramírez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL.

Cancer Res. 2006 Jan 1;66(1):427-34.

7.

Identification of new biomarkers for clinical trials of Hsp90 inhibitors.

Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, Fan J, Zhang L, Biamonte M, Brekken J, Lundgren K, Burrows F.

Mol Cancer Ther. 2006 May;5(5):1256-64.

8.

Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.

Le HC, Lupu M, Kotedia K, Rosen N, Solit D, Koutcher JA.

Magn Reson Med. 2009 Nov;62(5):1112-9. doi: 10.1002/mrm.22137.

9.

Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.

Glunde K, Jie C, Bhujwalla ZM.

Cancer Res. 2004 Jun 15;64(12):4270-6.

10.

Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment.

Lodi A, Ronen SM.

PLoS One. 2011;6(10):e26155. doi: 10.1371/journal.pone.0026155. Epub 2011 Oct 12.

11.

Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.

Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T; Australian Prostate Cancer BioResource, Tilley WD, Butler LM.

Clin Cancer Res. 2012 Jul 1;18(13):3562-70. doi: 10.1158/1078-0432.CCR-12-0782. Epub 2012 May 9.

12.
13.

Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.

Li Y, Zhang T, Schwartz SJ, Sun D.

Nutr Cancer. 2011;63(7):1151-9. doi: 10.1080/01635581.2011.596645. Epub 2011 Aug 29.

14.

HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.

Ko JC, Chen HJ, Huang YC, Tseng SC, Weng SH, Wo TY, Huang YJ, Chiu HC, Tsai MS, Chiou RY, Lin YW.

Regul Toxicol Pharmacol. 2012 Dec;64(3):415-24. doi: 10.1016/j.yrtph.2012.10.003. Epub 2012 Oct 13.

PMID:
23069143
15.

Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.

Schwock J, Pham NA, Cao MP, Hedley DW.

Cancer Chemother Pharmacol. 2008 Apr;61(4):669-81. Epub 2007 Jun 20.

PMID:
17579866
16.

Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.

Zajac M, Gomez G, Benitez J, Martínez-Delgado B.

BMC Med Genomics. 2010 Oct 4;3:44. doi: 10.1186/1755-8794-3-44.

17.

Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.

Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A.

J Exp Ther Oncol. 2008;7(3):183-93.

PMID:
19066127
18.
19.

Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.

Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA.

J Surg Res. 2012 Jul;176(1):147-53. doi: 10.1016/j.jss.2011.09.017. Epub 2011 Oct 5.

PMID:
22099584
20.

The effects of Hsp90 expression alteration on spinal metastases of breast carcinoma.

Yan W, Xiao J, Liu T, Huang W, Yang X, Wu Z, Huang Q, Qian M.

Tumour Biol. 2013 Jun;34(3):1391-7. doi: 10.1007/s13277-012-0584-z. Epub 2013 Mar 1.

PMID:
23456764
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk